IPH 4102

Drug Profile

IPH 4102

Alternative Names: Anti-KIR3DL2 cytotoxic mAb; IPH 41 programme; IPH 4101; IPH41; IPH4102

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Genoa
  • Developer Innate Pharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action KIR3DL2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cutaneous T cell lymphoma

Most Recent Events

  • 16 Oct 2017 Final efficacy data from a phase I trial in Cutaneous T-cell lymphoma released by Innate Pharma
  • 15 Jun 2017 Updated efficacy, pharmacodynamics and adverse events data from a phase I trial in Cutaneous T-cell lymphoma presented at the International Conference on Malignant Lymphoma (ICML-2017)
  • 14 Jun 2017 IPH 4102 receives Orphan Drug status for Cutaneous T-cell lymphoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top